# SNV4818 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06736704/  
OnCo record `nct06736704` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant and Palbociclib in advanced solid tumours, run by Pikavation Therapeutics, Inc., now recruiting.

## Summary

SNV4818 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06736704 by Pikavation Therapeutics, Inc., with 320 participants planned, started 2025-02-20 and due to reach its primary completion in 2027-04. Interventions recorded: SNV4818, Fulvestrant and Palbociclib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06736704
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors
- Sponsor: Pikavation Therapeutics, Inc.
- Enrolled: 320

## Sources

- ClinicalTrials.gov NCT06736704: https://clinicaltrials.gov/study/NCT06736704

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Palbociclib](https://onco.cc/drugs/palbociclib/)

---
JSON: https://onco.cc/api/v1/entities/nct06736704.json